As of May 27, 2025, Relmada Therapeutics Inc (RLMD) reports a ROE (Return on Equity) of -225.15%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Relmada Therapeutics Inc's ROE (Return on Equity)
Over recent years, Relmada Therapeutics Inc's ROE (Return on Equity) has shown a stable trend. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2024-12-31 | -225.15% |
| 2023-12-31 | -115.74% |
| 2022-12-31 | -111.85% |
| 2021-12-31 | -60.37% |
| 2020-12-31 | -56.31% |
This slight downward trend highlights how Relmada Therapeutics Inc manages its efficiency in generating profits from shareholders' equity over time.
Comparing Relmada Therapeutics Inc's ROE (Return on Equity) to Peers
To better understand Relmada Therapeutics Inc's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Relmada Therapeutics Inc (RLMD) | -225.15% |
| Redhill Biopharma Ltd (RDHL) | 1155.92% |
| Urovant Sciences Ltd (UROV) | 252.98% |
| Seelos Therapeutics Inc (SEEL) | 113.05% |
| Eli Lilly and Co (LLY) | 74.62% |
| Zoetis Inc (ZTS) | 52.12% |
Compared to its competitors, Relmada Therapeutics Inc's ROE (Return on Equity) is among the lowest compared to peers, which may indicate less effective deployment of shareholders' capital.